On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyond endoscopy, setting a new potential standard for the evaluation of therapeutic response Mirikizumab is an ...

Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Inflammation due to the overactivation of the IL-23 ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go beyon ...